Despite Continuous Dip In Covid-19 Vaccine Sales, BioNTech Manages To Post Q1 Profit, Reaffirms Guidance

BioNTech SE BNTX reported Q1 FY23 revenues of €1.28 billion, down from €6.37 billion a year ago, mainly due to lower commercial revenues from the supply and sales of the company's COVID-19 vaccines worldwide.

The company posted Q1 diluted EPS of €2.05, down from €14.24 a year ago.

Also ReadEuropean Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals

The company says the COVID-19 vaccine franchise is focused on vaccine adaptation readiness ahead of the fall season and advancing next-generation vaccine candidates and combinations.

"In the first quarter of 2023, we expanded our toolkit of cutting-edge technologies to new modalities and added a novel immune checkpoint inhibitor candidate targeting CTLA-4 and two investigational antibody-drug conjugates to our arsenal against cancer," said Ugur Sahin said, CEO & Co-Founder.

"For the remainder of 2023, we are focused on advancing our disruptive platforms against solid tumors and accelerating clinical programs in infectious diseases of high global need," Sahin added.

Outlook: BioNTech reiterates FY23 COVID-19 vaccine revenue of approximately €5 billion compared to €17.1 billion in 2022.

Price Action: BNTX shares are up 3.57% at $112.30 during the premarket session on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsLarge CapNewsHealth CareMoversGeneralwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!